<DOC>
	<DOCNO>NCT02042833</DOCNO>
	<brief_summary>This observational study evaluate patient ' perception treatment erythropoiesis-stimulating agent patient chronic kidney disease dialysis . Eligible patient initiate treatment Mircera ( methoxy polyethylene glycol-epoetin beta ) follow 6 month .</brief_summary>
	<brief_title>An Observational Study Patients ' Perception Treatment With Erythropoiesis-Stimulating Agents Patients With Chronic Kidney Disease Not Dialysis ( PERCEPOLIS )</brief_title>
	<detailed_description />
	<mesh_term>Hematinics</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Patients chronic kidney disease dialysis ( without previous renal transplantation ) Treated ESA time visit Patients treat physician decide initiate Mircera medical reason commencement study Initiation treatment Mircera inclusion visit Accepting able complete ESA preference questionnaire Participation clinical trial anemia Treatment Mircera 3 month inclusion Dialysis plan next 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>